Table 4 Association between patients' characteristics and MEIS1 gene expression
From: Evaluation of the HOXA9 and MEIS1 genes as a potential biomarker in adult acute myeloid leukemia
MEIS1 low expression (n = 16) | MEIS1 over-expression (n = 75) | p value | |
|---|---|---|---|
Age (years) | 32.5 (19–57) | 33.5 (18–65) | 0.938 |
TLC(×103/mm3) | 40.7 (3.8–281.7) | 38.9 (1–440) | 0.499 |
HB (g/dl) | 7.5 (6.1–9.8) | 8 (2.3–13) | 0.558 |
Platelet count (×103/mm3) | 36 (9–297) | 35 (5–240) | 0.853 |
PB blast (%) | 72.5 (20–95) | 50 (0–98) | 0.205 |
BM blast (%) | 74 (25–97) | 70 (14–95) | 0.631 |
Sex | |||
Male | 9 (56.3%) | 41 (54.7%) | 0.908 |
Female | 7 (43.8%) | 34 (45.3%) | |
Hepatomegaly | |||
Positive | 4 (25.0%) | 23 (30.7%) | 0.770 |
Spleenomegaly | |||
Positive | 6 (37.5%) | 17 (22.7%) | 0.221 |
Lymphadenopathy | |||
Positive | 4 (25.0%) | 26 (34.7%) | 0.566 |
BM cellularity | |||
Hypercellular | 12 (75.0%) | 58 (77.3%) | 0.903 |
Hypocellular | 1 (6.3%) | 6 (8.0%) | |
Normocellular | 3 (18.8%) | 11 (14.7%) | |
FAB | |||
M1 | 4 (25.0%) | 7 (9.3%) | 0.313 |
M2 | 6 (37.5%) | 32 (42.7%) | |
M4 | 5 (31.3%) | 19 (25.3%) | |
M5 | 1 (6.3%) | 16 (21.3%) | |
M7 | 0 (0.0%) | 1 (1.3%) | |
MPO | |||
Positive | 16 (100%) | 72 (96.0%) | 1.0 |
CD13 | |||
Positive | 16 (100.0%) | 75 (100.0%) | NA |
CD33 | |||
Positive | 16 (100.0%) | 75 (100.0%) | NA |
CD14 | |||
Positive | 8 (50.0%) | 36 (48.0) | 0.884 |
CD61 | |||
Positive | 0 (0.0%) | 1(1.3%) | 1.00 |
Aberrant IPT markers | |||
Normal | 9 (56.3%) | 64 (85.3%) | 0.014 |
Aberrant | 7 (43.8%) | 11 (14.7%) | |
IPT | |||
Monocytic | 1 (6.3%) | 6 (8%) | 0.755 |
Myeloid | 11 (68.8%) | 41 (54.7%) | |
Myelomonocytic | 4 (25.0%) | 27 (36%) | |
Megakaryoblasic | 0 (0.0%) | 1 (1.3%) | |
FLT3(ITD) | |||
Wild | 14 (87.5%) | 63 (84%) | 0.725 |
Mutant | 2 (12.5%) | 12 (16.0%) | |
Cytogenetic risk | |||
Favorable | 2 (12.5%) | 12 (16.0%) | 0.348 |
Intermediate | 13 (81.3%) | 48 (64.0%) | |
Adverse | 1 (6.3%) | 15 (20%) | |
Response to treatment | |||
CR | 10 (62.5%) | 58 (77.3%) | 0.221 |
No CR | 6 (37.5%) | 17 (22.7%) | |
Survival analysis | |||
Median OS | 9.000 | 12.470 | 0.695 |
Cumulative OS after 3 months | 21.1% | 31.8% | |
Median DFS | 14.070 | 25.630 | 0.351 |
Cumulative DFS after 3 months | 25.4% | 44.7% | |